At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,235 enrolled
Drug / intervention
Formulation A +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY ADULTS
In Brief
A Phase 2 clinical trial evaluating Formulation A, Formulation B, and 1 other intervention for Respiratory Tract Infections. Completed, enrolled 1,235 participants across 40 sites.
Detailed Summary
The study will describe the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations when administered alone or concomitantly with seasonal inactivated influenza vaccine (SIIV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Tract Infections
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedMay 2018
Primary CompletionNov 2019
Study CompletionDec 2020
TodayJul 2026
First PostedMay 18, 2018
Enrollment StartApr 18, 2018
Primary CompletionNov 20, 2019
Study CompletionDec 28, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.1 years ago
Interventions
Formulation Abiological
RSV vaccine
Formulation Bbiological
RSV vaccine
Placebobiological
Placebo